Can citrus compounds or allergy meds prevent G-CSF bone pain?
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether taking a combination of two natural compounds (diosmin and hesperidin) similar to those from citrus fruits, or the allergy medicine loratadine, can prevent or reduce bone pain caused by G-CSF injections—a common treatment to boost white blood cells in people with blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You are receiving a G-CSF (a shot to help increase white blood cells) for either leukemia/lymphoma treatment or after a stem cell transplant using your own cells
- You may or may not have bone pain from the G-CSF
- You do not have a solid tumor cancer
- You are not pregnant or breastfeeding
- You do not have allergies to loratadine, diosmin-hesperidin, or filgrastim
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
This trial tests loratadine (an allergy medicine) to see if it can prevent bone pain caused by a growth-factor injection used during lymphoma or multiple myeloma treatment. It may help reduce pain around the time you get that injection and your upcoming stem cell transplant.
This early trial studies whether loratadine (an allergy medicine) can reduce bone pain caused by G-CSF, which is used to help your body collect stem cells. If you have multiple myeloma and are preparing for stem cell mobilization, this may make treatment-related bone pain more tolerable.
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.